DiseasesKeytruda (pembrolizumab) is approved for cancer solid tumors
Keytruda Keytruda (pembrolizumab) is indicated for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors that have been identified as having a biomarker referred to as microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). Indications Metastatic Melanoma. Unresectable Melanoma. Refractory, metastatic Non-small cell lung cancer. Keytruda mechanism of Action Keytruda works…
May 23, 2017
